Tacrolimus Topical and Nifedipine Interaction

Understanding the Tacrolimus Topical and Nifedipine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Tacrolimus Topical belongs to the Calcineurin Inhibitor (Topical) class and Nifedipine belongs to the Calcium Channel Blocker class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Nifedipine slows down how your body breaks down tacrolimus, which can cause the drug to build up to unsafe levels in your blood. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Tacrolimus Topical has 25 total documented interactions on file in this dataset, and Nifedipine has 26. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to monitor your blood levels closely and adjust your dose to prevent serious side effects. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Tacrolimus Topical or Nifedipine based on a web page, speak with your prescriber or pharmacist before making any change.